Raltitrexed

Drug Profile

Raltitrexed

Alternative Names: ICI D 1694; Raltitrexed disodium; Tomudex; ZD 1694

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator The Institute of Cancer Research
  • Developer AstraZeneca; BTG; Centre Georges Francois Leclerc; Hospira; National Cancer Institute (France)
  • Class Antineoplastics; Quinazolines; Small molecules; Thiophenes
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Mesothelioma

Most Recent Events

  • 03 Sep 2015 Hospira has been acquired by Pfizer
  • 01 Dec 2010 Phase-II clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in France (Intra-arterial) (NCT01348412)
  • 12 Oct 2010 Registered for Malignant pleural mesothelioma in Czech Republic (reference member state) (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top